ArticleBMC microbiology2025
Association of the microbiome with pre-epithelial barrier impairment in individuals with laryngopharyngeal reflux.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLaryngopharyngeal reflux (LPR) involves microbiota dysbiosis and changes in the salivary pre-epithelial barrier. However, the interaction between these factors, which impact gastroesophageal reflux disease (GERD), remains unknown. Herein, we conducted a comparative cross-sectional study enrolling 36 individuals with LPR, diagnosed by Diagnostic Potential of Hydrogen Monitoring System (Dx-pH monitoring), and 39 healthy controls. The salivary flow and key salivary pre-epithelial barrier factors, epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), mucin 5B (MUC5B), mucin 7 (MUC7), secretory immunoglobulin A (SIgA), were assessed along with microbiome examination.
resultsLPR individuals exhibited a reduced salivary flow (P = 0.008) and salivary secretion of EGF (P = 0.029), TGF-α (P = 0.028) and MUC5B (P = 0.010) when compared to those of healthy controls. Additionally, compared with those in the control group, the 5-minute secretory quantity of MUC7 (P = 0.086) and SIgA (P = 0.255) were also lower in the LPR patient group, but these differences were not statistically significant (P > 0.05). Distinct bacterial communities were identified in the LPR group, with a significant increase in acid-resistant bacteria, including Prevotella and Veillonella. Additionally, the abundance of Prevotella (γ= -0.639, P = 0.002) was significantly negatively correlated with EGF concentration in LPR patients.
conclusionOur findings demonstrate that LPR is associated with both distinct salivary microbial profiles and disruption of the pre-epithelial mucosal barrier constituents. These observations support a potential role for salivary microbiota dysbiosis in the pathogenesis of LPR, highlighting a novel interconnection between microbial community perturbations and mucosal barrier dysfunction in this disease. LEVEL OF EVIDENCE：: 4
trial registrationNo. ChiCTR2400091947. Registered on November 6,2024 retrospectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.